You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

BUSPAR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Buspar, and when can generic versions of Buspar launch?

Buspar is a drug marketed by Bristol Myers Squibb and is included in two NDAs.

The generic ingredient in BUSPAR is buspirone hydrochloride. There are nineteen drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the buspirone hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Buspar

A generic version of BUSPAR was approved as buspirone hydrochloride by IMPAX LABS INC on March 28th, 2001.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for BUSPAR?
  • What are the global sales for BUSPAR?
  • What is Average Wholesale Price for BUSPAR?
Summary for BUSPAR
Drug patent expirations by year for BUSPAR
Recent Clinical Trials for BUSPAR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Spaulding Rehabilitation HospitalPhase 2
University of LouisvilleEarly Phase 1
National Institute of Neurological Disorders and Stroke (NINDS)Early Phase 1

See all BUSPAR clinical trials

US Patents and Regulatory Information for BUSPAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb BUSPAR buspirone hydrochloride CAPSULE;ORAL 021190-001 Dec 20, 2000 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bristol Myers Squibb BUSPAR buspirone hydrochloride TABLET;ORAL 018731-003 Apr 22, 1996 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bristol Myers Squibb BUSPAR buspirone hydrochloride CAPSULE;ORAL 021190-004 Dec 20, 2000 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bristol Myers Squibb BUSPAR buspirone hydrochloride TABLET;ORAL 018731-004 Apr 22, 1996 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for BUSPAR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol Myers Squibb BUSPAR buspirone hydrochloride TABLET;ORAL 018731-003 Apr 22, 1996 ⤷  Sign Up ⤷  Sign Up
Bristol Myers Squibb BUSPAR buspirone hydrochloride TABLET;ORAL 018731-003 Apr 22, 1996 ⤷  Sign Up ⤷  Sign Up
Bristol Myers Squibb BUSPAR buspirone hydrochloride TABLET;ORAL 018731-002 Sep 29, 1986 ⤷  Sign Up ⤷  Sign Up
Bristol Myers Squibb BUSPAR buspirone hydrochloride CAPSULE;ORAL 021190-001 Dec 20, 2000 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.